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Genomic intensive care: should we
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Dominic JC Wilkinson,1,2,3 Christopher Barnett,4,5 Julian Savulescu,1
Ainsley J Newson6
In newborn intensive care units (NICUs),
the science and art of prognostication
often have life and death implications.
Approximately 5% of infants admitted to
NICU die.1 The majority of deaths are
preceded by decisions to withdraw or
withhold life-sustaining treatment,1 fol-
lowing discussions between the family and
clinical team. These decisions are based
on an assessment of an infant’s chance of
survival and on the predicted duration
and nature of the infant’s survival if treat-
ment is provided.2
A variety of clinical, biochemical,
genetic and radiological tests have trad-
itionally been employed to estimate prog-
nosis in the NICU. While chromosomal
microarray is now commonly used for
critically ill neonates with congenital mal-
formations, new forms of genetic and
genomic testing3 have started to become
available in intensive care.4 They could
aid critical care decision-making by pre-
dicting functional outcome, important
comorbidities5 or poor prognosis despite
treatment4 (box 1).
GENOMIC TESTING
Genetic testing is already available, and is
widely used in newborn intensive care.
This includes conventional karyotyping,
ﬂuorescent in-situ hybridisation, array
comparative genomic hybridisation
(aCGH) and sequencing of a gene or
genes using Sanger (‘traditional’) DNA
sequencing in situations where a single
gene disorder is suspected. More recently,
multiple gene sequencing panels using
next-generation sequencing (NGS) techni-
ques, whole exome sequencing (WES;
sequencing of the coding/exonic regions
of the genome) and whole genome
sequencing (WGS) have become increas-
ingly available in the clinical setting.3 6
These newer methods differ in both the
potential depth and breadth of analysis
and information obtained.
Until recently, WES and WGS have
largely been used in research. However,
the rapidly falling cost and increasing
speed of NGS have made clinical use
possible. Some centres are gaining experi-
ence in the use of WES and WGS in
selected patients with difﬁcult-to-diagnose
illness.5 7
Genomic testing capable of diagnosing
hundreds of genetic conditions in ‘one
test’ might have particular application in
the NICU since this is the time point
when many congenital and genetic disor-
ders become apparent. The full phenotype
of the illness may not yet be apparent,
meaning that diagnosis by conventional
means is often delayed. In one recent
series, WGS with targeted analysis was
completed in as little as 50 h, yielding a
genetic diagnosis in 20 out of 35 infants
thought to have a likely monogenic dis-
order tested prospectively.8 The authors
described a newborn infant with refrac-
tory seizures, from whom life support was
withdrawn after 5 weeks of intensive care
and multiple investigations and trials of
therapy. WGS revealed a homozygous
gene mutation previously described in a
lethal neonatal seizure disorder.4 8
Different uses of genomic testing
Genomic testing (ie, NGS panels, WES,
WGS) could theoretically be used at mul-
tiple different time points, for example,
preconception, preimplantation, ante-
natally or postnatally. Here, we focus on
the use of genomic testing after birth in
critically ill infants.
Genomic testing may be used for diag-
nosis. It may also be used prognostically
for critically ill infants in several different,
though overlapping, ways. Genomic
testing might be used for treatment modi-
ﬁcation to identify speciﬁc pharmaco-
logical or other treatments that are likely
or unlikely to be of beneﬁt given an
infant’s outcome. Even in the absence of
speciﬁc treatment, it could be used for
anticipation or information, providing
parents with advance knowledge of poten-
tial future problems as well as the risk of
recurrence in future offspring. Genomic
testing might also be used to help inform
Box 1 Genomic testing and ethical dilemmas: hypothetical case studies
1. A term newborn infant is born in poor condition in the setting of meconium-stained
liquor and variable decelerations. The infant requires resuscitation, including
intubation and is transferred to the neonatal intensive care unit. The infant has early
evidence of encephalopathy with refractory seizures. Should the infant have rapid
whole genome or exome sequencing to look for a possible underlying inborn error of
metabolism or epileptic encephalopathy?4
2. A newborn infant is born extremely preterm at 24 weeks’ gestation. At 1 week of
age, the infant remains critically unwell, and has developed evidence of sepsis and
necrotising enterocolitis. Chromosomal microarray testing had been performed on
cord blood, and now reveals a microdeletion that has been associated with an
increased risk of autism and schizophrenia. Should this information be revealed to
the infant’s parents? Should it be used in decision-making about continuation of
intensive care and surgery for the infant’s necrotising enterocolitis?
3. A newborn infant was diagnosed with complex congenital heart disease antenatally.
The infant’s parents declined amniocentesis following the anomaly scan as it would
not have changed their decision to continue the pregnancy. Postnatally, the infant is
conﬁrmed to have hypoplastic left heart syndrome. The infant has minor dysmorphic
features. The infant’s parents are requesting full active treatment, and local practice
includes the option of cardiac transplantation. Should the infant have genomic testing
prior to listing for transplantation? What features on testing would make the infant
ineligible for transplantation?
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treatment limitation, either because it is
relevant to the best interests of the infant,
to parental preferences for treatment or to
resource allocation.
There will be different levels or degrees
of inﬂuence of genomic testing over the
above categories of clinical decisions. In
some situations, information from
genomic testing may make only a small
contribution to parents’ and doctors’ deci-
sions about treatment. Often, regardless
of whether there is a genomic test result
that indicates a problem, there is sufﬁcient
uncertainty about the beneﬁts of continu-
ing treatment (or a sufﬁciently worrying
prognosis) that treatment limitation would
be reasonable. But in other situations,
genomic testing could have more inﬂu-
ence. Treatment would continue in the
absence of a speciﬁc test result, yet in its
presence, treatment limitation will be ser-
iously considered.
THE ETHICS OF GENOMIC TESTING
FOR CRITICALLY ILL INFANTS
The over-arching ethical considerations
around genomic testing for critically ill
infants in the NICU are summarised in
table 1. These echo those that have been
extensively discussed around genomic
testing elsewhere.9 10
The beneﬁts and risks of such testing in
critically ill infants could lead to several
different strategies. Faced with the chal-
lenges of interpretation of genomic infor-
mation and the implementation of testing
in critically ill infants, one option would
be to refrain from using newer forms of
genomic tests in the NICU, at least until
their clinical utility and validity are better
demonstrated. However, in the NICU, it
appears that genomic testing will at least
sometimes be justiﬁable. In case 1 (box 1),
for example, identiﬁcation of a mutation
in STXBP1 would lead to diagnosis of
Ohtahara syndrome, for which, folinic
acid therapy may be helpful.20 In the
recent case series, WGS had a much
higher rate of genetic diagnosis than con-
ventional testing (20/35 infants vs 2/35
infants), and led to a substantial favour-
able impact on acute clinical management
in 4 out of 20 infants.8 For example, in
one infant with refractory hypoglycaemia,
identiﬁcation of a gene for focal familial
hyperinsulinism led to modiﬁcation of
planned surgery with subsequent reso-
lution of symptoms.8 Genomic testing
could equally lead to avoidance of non-
beneﬁcial treatment. Six of the 20 infants
receiving a genetic diagnosis in the WGS
study were subsequently shifted to pallia-
tive care. A genomics clinic in Wisconsin
has described a critically ill infant with
severe cryptogenic liver disease in whom
WGS identiﬁed a mutation in the C10orf2
gene, previously associated with progressive
Table 1 A summary of general ethical considerations for and against genomic testing in the NICU
In favour of genomic testing in the NICU Points of concern with genomic testing in the NICU
▸ Actionability
Genomic testing may yield information that is relevant for medical
decision-making in the NICU
A test is generally thought to be of value if it generates information that has
both clinical utility and validity; providing actionable information11
However, it will often be difficult to predict whether genomic testing will lead
to actionable information (particularly while genomic knowledge is at an early
stage), and it may do so only in a minority of cases
▸ Cost-effectiveness
Genomic testing may save costs by preventing the need for expensive and
prolonged diagnostic testing (including traditional Sanger sequencing), as well
as by avoiding prolonged, expensive and non-beneficial intensive care
treatment.4 The costs of genomic tests have fallen rapidly
However, the after-sequencing costs, including bioinformatics and
interpretation may be substantial12
▸ Access to testing
Genome testing will soon be available to parents prenatally or postnatally
from private companies. It would potentially be better to provide information
within a healthcare system with access to support and interpretation. It might
also be unfair to deny parents (who cannot afford it) the option of testing
that might be relevant to clinical management decisions
▸ Consistency
The principles of use of genomic testing in the NICU are similar to more
conventional investigations that are widely used, such as karyotype,
single-gene sequencing, MRI or metabolic tests
▸ False-positive results
Genomic testing may lead to incorrect diagnoses. Even very accurate tests with high
sensitivity and specificity yield significant numbers of false positives when applied to
a very large number of genes.13 False-positive results may also arise because
variations within or adjacent to disease-causing genes may be predicted by
commonly used software packages (PolyPhen, Mutation Taster) to be pathogenic,
but in the fullness of time are proven not to be. A significant proportion of
mutations that were previously identified in published literature as causative of
disease are now believed to be incorrect14
▸ Incidental findings
Testing could reveal genetic mutations that confer risk of adult-onset illnesses such
as cancer or neurodegeneration.13 15 16 Release of this information may have no
bearing on current clinical decision-making, prevents children deciding whether to
undergo testing in the future (removing their right to an ‘open future’) and could
lead to psychological harm in the family17
However, diagnosis of these conditions could be beneficial for the child
psychologically and in terms of the child’s autonomy (eg, by helping the child make
decisions about education and career),18 and could have major implications for the
health of the child’s parents.16 See also ‘genetic privacy’ below
▸ Uncertain results
Genome testing may identify variants of uncertain significance (VUS).19 A VUS is a
DNA sequence alteration or copy number variation (deletion/duplication), which is
not common in the general population, but for which a definite link to human
disease cannot be made on current data. Some VUS’ will be redefined as
pathogenic mutations in the near future as more cases are ascertained; others will
be classified as non-pathogenic with time. For this reason, post-test interpretation
can be challenging, highly complex, non-definitive and potentially confusing for
parents
▸ Genetic privacy
Testing could impact on future employment or ability to access insurance.
Identification of genetic abnormalities in the child may also lead, by inference or
further testing, to identification of mutations in the parents and extended family
However, these concerns apply equally to genetic and other tests already in use and
accepted in the NICU. Notions of ‘privacy’ with respect to children are also difficult
to uphold. In some jurisdictions, these concerns may be partly addressed by existing
legislation or regulation19
This table necessarily condenses a complex debate, which is discussed in depth elsewhere.6 7 9 10
Opposing considerations are shown in italics.
NICU, newborn intensive care unit.
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neurological deterioration, which contribu-
ted to a decision not to proceed with liver
transplantation.5
Further, these sequencing techniques
are highly likely to move into clinical
practice over the next few years to com-
plement or replace existing tests. aCGH
has already replaced karyotyping as a
ﬁrst-line investigation for congenital
abnormalities,21 and raises similar issues
to WES and WGS (eg, case 2), although
on a more contained scale.10 Even if
unavailable through a public healthcare
system, genomic testing may be sought
privately, for example, through sequen-
cing of fetal DNA in maternal plasma.22
Finally and importantly, although the
scale of the problems may be greater, the
ethical issues raised by the newer tech-
nologies (WES/WGS) are similar in prin-
ciple to the ethical issues raised by other
genetic tests and indeed other diagnostic
and prognostic tests in the NICU.
The key question, we suggest, is, there-
fore, not whether genomic testing is used,
but when and how it is used.
When should genomic testing be used
in the NICU?
Targeted diagnostic testing
The most obvious and least controversial
policy for implementation of genomic
testing in the medium term is its use in a
targeted fashion for diagnosis (eg, case 1,
box 1).10 This would involve careful selec-
tion of patients for whom genomic testing
is most likely to identify a pathogenic
mutation. Examples include infants with a
suspected, but undiagnosed, metabolic
condition where genomic testing could
provide diagnostic information, not
available from biochemical screening.
There are numerous conditions that are
not included on newborn biochemical
screening tests that would be diagnosed
on genome testing, including mucopoly-
saccharidoses (Hunter syndrome,
Hurler syndrome), congenital disorders
of glycosylation and disorders of choles-
terol metabolism (Smith–Lemli–Opitz
syndrome).
Genomic testing might be used in place
of repeated Sanger gene sequencing for
infants with dysmorphism, complex
neuromuscular presentations (eg, arthro-
gryposis), or congenital abnormalities that
could be related to multiple different
genes. This could increase the diagnostic
yield in this group of infants.8
Targeted prognostic testing
Genomic testing could (and arguably
should) also be used to provide additional
prognostic information that would be
potentially actionable. This includes the
examples of cases 2 and 3 (box 1). While
the general presumption is not to test
young children for adult-onset conditions,
the setting of critical illness in the NICU
means that a different approach may be
warranted. Future health states, even if
not treatable or preventable (and perhaps
especially if they are not treatable or pre-
ventable) may be relevant.
There are two arguments in favour of a
more permissive approach to testing here.
The ﬁrst is related to the ethical uncer-
tainty inherent in the NICU.2 One way of
understanding the best interests approach
to treatment decisions in the NICU is as
an attempt to weigh up the beneﬁts
against the burdens of providing treat-
ment. For infants with very severe con-
genital malformations, hypoxic brain
injury or extremely premature infants at
the borderline of viability, there is a sufﬁ-
ciently ﬁne balance between beneﬁts and
burdens that some families will choose
treatment continuation, while others
choose treatment withdrawal. There can
often be no ethical presumption one way
or the other: both are reasonable choices
to make. Additional burdens in the future
life of an infant with seriously compro-
mised health (eg, an additional risk of
mental illness, cognitive impairment or
early onset malignancy) might be judged
by some parents to tip the balance in
favour of not continuing treatment.
Conversely, the absence of additional
burdens might lead parents to request
continued treatment.
The second reason in favour of testing
is that these situations may be judged to
fall into a ‘zone of parental discretion’.2 23
Information about an infant’s long-term
prognosis may be relevant both to
parents’ own interests and to their evalu-
ation of the interests of the child. Of
course, genomic testing may not yield
information that parents judge relevant to
their own or their child’s interests. It may
even yield unhelpful information about
possible future risks with wide CIs.
However, this does not mean that there
should be a presumption against testing.
Rather, following appropriate counselling
and discussion, parents’ considered views
and values should be given serious consid-
eration in jointly reaching a decision.
In cases like case 2 and case 3, a
broader range of information should be
sought than in diagnostic testing. Case 2
and case 3 are indicative of those infants
where there is a genuine question about
whether or not to provide treatment.
Prognostic testing may, therefore, be
appropriate here as speciﬁc test results
may be important and relevant to parents
and treating team. In contrast, prognostic
testing should not routinely be conducted
for infants where there is no pre-existing
question about provision of life-sustaining
treatment. For example, given the uncer-
tainties about results and the ethical con-
siderations summarised in table 1, it
would not be appropriate to embark on
prognostic genomic testing for moderately
or mildly premature infants, or infants
with readily treatable congenital abnor-
malities. (Diagnostic testing in the latter
cases may still be relevant if there is suspi-
cion of an underlying syndrome).
One further interesting question,
beyond the scope of this paper, is whether
in cases like case 3, testing may proceed
even in the absence of parental consent.
Here, prognostic information would be
highly relevant to decisions about treat-
ment on the basis of the child’s best inter-
ests or on the basis of resource allocation.
How should genomic testing be used
in the NICU?
There are several key strategies for addres-
sing the ethical challenges arising from
the use of genomic testing in critically ill
infants.
First, it will clearly be important for
parents to have an opportunity to make
an informed and considered decision
before agreeing to genomic testing. Some
parents may prefer not to receive informa-
tion of this nature, and we should
presume that existing tenets of genetic
counselling, such as non-directiveness,
should be respected in NICU genomic
testing. As a minimum, pretest counselling
should address the range of information
that would be relevant to parents’ and
doctors’ decisions about treatment, and
should include the possibility of identify-
ing variants of unknown signiﬁcance and
incidental ﬁndings. Where there is
advance warning (eg, following detection
of serious abnormalities on antenatal
ultrasound), it may be preferable to
perform such tests as a part of prenatal
care. Counselling could then be under-
taken prior to birth, and information
would readily be available to treating
doctors if a newborn then required inten-
sive care.
However, facilitating informed deci-
sions in the NICU will not be straightfor-
ward. We do not yet know how consent
processes (particularly in the setting of
parents of a critically ill infant) will be
able to deal with the complexity of infor-
mation and the full range of possible
results of genomic testing. We do know
that, if adhering to current models, it is
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likely to be complex and time-consuming.
Genomic testing may, thus, require
reassessment and revision of traditional
models of informed consent.24
Second, given the large number of inci-
dental and uncertain ﬁndings from
genomic testing, it will be important to
stratify results. Test results might be
grouped into different categories based on
the likelihood of them relating to the
child’s current or imminent clinical pres-
entation; while incidental ﬁndings could
be grouped based on clinical validity and
expected utility to parents; to the extent
that these things can be known.15 There
remains considerable debate about
whether some serious conditions identi-
ﬁed incidentally on genomic testing in
children should be reported.16 25 The
general approach taken to incidental ﬁnd-
ings should be the same for infants as for
other children who cannot consent to
testing. However, as noted above, for some
critically ill infants (where life-sustaining
treatment is already considered ethically
optional), information about illness or
function in later life that would be
regarded as ‘incidental’ in other children
may be relevant to parental decision-
making and, hence, ‘actionable’. A decision
to reveal or to ﬁlter out particular inciden-
tal ﬁndings should, in principle, be guided
by what parents consider important for
their child’s best interests. For example,
doctors might ask parents what informa-
tion would change their mind about con-
tinuing or discontinuing treatment. In
practice, this may be extremely challenging
for parents to determine in advance.
The largest ethical dilemmas from
genomic testing in the NICU will be deter-
mining whether, when and how genomic
testing results should inﬂuence treatment
decision-making in intensive care. To this
end, a third strategy for genomic testing
will be to use existing ethical frameworks
for clinical decision-making in the NICU,
particularly in the face of uncertainty. For
example, the question of whether to
perform surgery in case 2 arguably turns
on an assessment of the infant’s best inter-
ests, as well as on the interests and wishes
of the infant’s parents.2 26 Given the high
rate of morbidity following surgery, it
would usually be regarded as appropriate
to limit treatment and not proceed with
surgery if there was agreement between
the clinical team and the infant’s parents.
Cranial ultrasound evidence of severe
intraventricular haemorrhage (IVH) would
often be taken as supporting such a deci-
sion. It would, therefore, be reasonable to
provide the infant’s parents with genomic
test results that might indicate risk of long-
term problems at least of a similar severity
to severe IVH.
In case 3, there might be concerns
about genomic testing leading to discrim-
ination if genetic information were used
to rule out surgery. However, a number of
changes revealed on genomic testing
might have relevance for the likely success
of transplantation or the rate of complica-
tions, factors relevant to both the infant’s
best interests and considerations of avail-
able health resources within a public
healthcare system.27 28 To this end, while
the future implications of genomic infor-
mation are important, their present utility
should also be considered; particularly
when it is likely to inﬂuence an imminent
clinical decision.
CONCLUSIONS
The genomic era is coming to the NICU as
to other areas of medicine, and will play a
role in neonatal treatment decisions. The
scale of the information generated by this
technology will both inform and cloud
clinical decision-making. Just as with other
new tests adopted in the NICU (eg, MRI),
clinicians will need to treat results of
genomic testing with caution, and have a
critical eye to the evidence base for predic-
tions. Parents will need to be counselled,
ideally under the care of a clinical genetics
service, about the uncertain and perhaps
changing nature of some results.29
Bioinformatic analysis of genome testing is
currently the rate-limiting step in providing
a timely result. Additionally, much of the
information needed to use genomic tests
for critical care decisions is not currently
available. This highlights the need to
collect data that efﬁciently links genome
testing results and neonatal long-term
outcome. One important practical question
(beyond the scope of this paper) relates to
decisions about which test to order
(eg, NGS panels, WES, WGS) and the
trade-off between information return, pro-
cessing time and cost. Again, the support
of a clinical genetics service will be crucial
for practitioners in the NICU. Genomic
testing in critically ill infants is bringing
to the fore difﬁcult ethical questions
about the thresholds for providing or
limiting treatment, and about the role of
parents in decisions. Neonatologists and
parents will continue to grapple with
those problems regardless of the tech-
nologies used to predict outcome in
intensive care. Although the genomic era
will not provide all of the answers, we
believe the rapidly advancing use of
genomic medicine will have long-lasting
impacts on neonatal care.
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